KMTSHealthcare · Medical Instruments & SuppliesKMTS Stock Forecast: Kestra Medical Technologies Ltd. Price Predictions for 2026-2027
The 7 Wall Street analysts covering Kestra Medical Technologies Ltd. hold a median 12-month price target of $30 — +25.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
KMTS stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Kestra Medical Technologies Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (61): Sales and profits are climbing, and climbing faster than before.
Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Kestra Medical Technologies Ltd. — and when they’d sell — is the membership.
KMTS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on KMTS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +25.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 July 2026 | Oppenheimer | Initiates | Perform | — |
| 21 July 2026 | Oppenheimer | Initiates | Perform | — |
| 15 July 2026 | BTIG | Maintains | Buy | $30 → $32 |
| 15 July 2026 | BTIG | Maintains | Buy | — |
| 9 Apr 2026 | Goldman Sachs | Maintains | Neutral | — |
| 7 Apr 2026 | BTIG | Reiterates | Buy | — |
| 25 Mar 2026 | BTIG | Reiterates | Buy | — |
| 18 Mar 2026 | BTIG | Reiterates | Buy | — |
| 15 Dec 2025 | Goldman Sachs | Maintains | Neutral | — |
| 12 Dec 2025 | Piper Sandler | Maintains | Overweight | — |
| 12 Dec 2025 | Wells Fargo | Maintains | Overweight | — |
| 18 Nov 2025 | BTIG | Initiates | Buy | — |
| 17 July 2025 | Wells Fargo | Maintains | Overweight | — |
| 16 Apr 2025 | Goldman Sachs | Maintains | Neutral | — |
| 31 Mar 2025 | Goldman Sachs | Initiates | Neutral | — |
| 31 Mar 2025 | Piper Sandler | Initiates | Overweight | — |
| 31 Mar 2025 | Stifel | Initiates | Buy | — |
| 31 Mar 2025 | Wells Fargo | Initiates | Overweight | — |
| 31 Mar 2025 | Wolfe Research | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
KMTS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Kestra Medical Technologies Ltd. (KMTS) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −4.9×
- Price / sales
- 14.7×
- Price / book
- 5.3×
- EV / EBITDA
- −9.4×
Cheaper than 90% of US stocks
Cheaper than 11% of US stocks
Cheaper than 20% of US stocks
Cheaper than 84% of US stocks
- Revenue growth (YoY)
- 66.2%
- Earnings growth (YoY)
- 66.2%
- Gross margin
- 54.8%
- Operating margin
- −137.4%
- Net margin
- −138.4%
Higher than 90% of US stocks
Higher than 81% of US stocks
Higher than 69% of US stocks
Higher than 12% of US stocks
Higher than 4% of US stocks
- Return on equity
- −56.6%
- Return on assets
- −25.7%
- Dividend yield
- —
Higher than 19% of US stocks
Higher than 16% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
KMTS vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KMTS appears on the weeks it earns a place.
Frequently asked questions about KMTS stock
What is the KMTS stock price forecast for 2026-2027?
The 7 Wall Street analysts covering Kestra Medical Technologies Ltd. have a median 12-month price target of $30, with estimates ranging from $28 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is KMTS stock a buy right now?
Of the 7 analysts covering Kestra Medical Technologies Ltd., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kestra Medical Technologies Ltd. 20 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank KMTS?
As at 1 Aug 2026, Kestra Medical Technologies Ltd. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (61 of 100).
Will KMTS stock go up?
No one can know that. What the data says: the median 12-month target from 7 analysts implies +25.1% from the last close, and Ticker Nerd's factor model ranks Kestra Medical Technologies Ltd. 20 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the KMTS stock forecast for 2030?
No analyst covering Kestra Medical Technologies Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KMTS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $28 to $32 over the next 12 months.
How has KMTS stock performed over the past year?
Kestra Medical Technologies Ltd. returned +56.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Kestra Medical Technologies Ltd. do?
Kestra Medical Technologies Inc. is a company specializing in the development and production of innovative medical devices.
About Kestra Medical Technologies Ltd.
Kestra Medical Technologies Inc. is a company specializing in the development and production of innovative medical devices. The core function of Kestra is to design wearable medical technologies aimed at improving patient outcomes in critical health areas. Primarily, the company engages in creating devices that focus on cardiac care, providing solutions that monitor, diagnose, and assist in the management of heart conditions. Kestra Medical Technologies addresses significant needs within the healthcare sector, particularly impacting the cardiology field by offering devices that enhance both the quality and efficiency of patient care. As a player in the medical technology industry, Kestra is positioned to influence patient health management trends and contribute to the advancement of medical device technologies. Its products serve as critical tools for healthcare providers aiming to offer cutting-edge care solutions.
CEO Mr. Brian Webster · 443 employees · United States · https://kestramedical.com